| |
Newsroom /
Health and Fitness
/
Healthcare
/
Angina Pectoris - Drug Pipeline Analysis and Market Forecasts to 2016
Angina Pectoris - Drug Pipeline Analysis and Market Forecasts to 2016
The Angina Pectoris Market is Forecast to Show Slow Growth until 2015
Hyderabad,
AP,
India
(prbd.net)
06/01/2010
"The Angina Pectoris Market"
GlobalData has estimated the global angina pectoris market to be valued at $10.7 billion in 2009. It is expected to grow to $11.4 billion by 2016 with a compound annual growth rate (CAGR) of 1%. This slow growth is primarily attributed to the expected approval of first-in-class investigational therapies from the mature pipeline such as Generx, potential stem cell therapies, coagulant Xa inhibitors, Rho-kinase inhibitors, factor VIIa/tissue factor protein complex inhibitors, and so on. However, the price of these new pharmaceuticals with marked improvements in safety and efficacy will definitely be high. Therefore, market penetration will be slow. Also, the period 2009-2016 will witness the expiry of the patents on major blockbuster drugs such as Lipitor (2011), Angiomax (2010) and Aggrastat (2012), paving the way for the genericization of these drugs. Therefore the angina pectoris market is expected to witness slow growth with the entry of many generics in the coming years – a scenario that is similar to the present market scenario.
GlobalData has found that the current competition in the angina pectoris market is weak and that the available treatment options are moderately successful in meeting the market demand. The products currently available in the market are associated with mediocre efficacy and safety profiles. Some of the serious side-effects associated with angina therapies are liver dysfunction, sexual dysfunction, headache, fatigue, bracycardia, worsening of heart failure, increased blood pressure, high mortality and so on. In addition to this, the current treatments offer poor quality of life due to a lack of efficacy in reducing cardiovascular events and mortality. Because the products currently in the market do not serve the unmet need, the market continues to present opportunities for stronger pipeline candidates. The unmet needs in the angina market are considered to be high and can be fulfilled by technologically advanced products with improved safety and efficacy profiles.
GlobalData has found that there are over 30 molecules in various stages of the pipeline. Generx, Rivarobaxan, Tedangin, Fasudil, RNAPc2 are all first-in-class molecules with great potential to increase indicators such as exercise treadmill test time, prolonged time for coronary events, change in angina incidence and to provide increased quality of life. These products are expected to meet the unmet needs in the angina pectoris market and to provide patients and physicians with increased options ultimately leading to increased competition within the market. Although switchovers are likely to happen due to the entry of generics into the market, the angina market will witness slow growth in the coming years.
GlobalData, the industry analysis specialist, has released its new report, “Angina Pectoris – Drug Pipeline Analysis and Market Forecasts to 2016”. The report is an essential source of information and analysis on the global angina pectoris market. The report identifies the key trends shaping and driving the global angina pectoris market. The report also provides an insight on the prevalent competitive landscape and the emerging players expected to change the market positioning of the existing market leaders. Most importantly, the report provides a valuable insight on the pipeline products within the global angina pectoris sector.
Or Visit our report store: http://www.globaldata.com/reportstore
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|